399 related articles for article (PubMed ID: 3082830)
1. Demonstration of intratumoral infiltration of tumor-specific Lyt-1+2- T cells mediating delayed-type hypersensitivity response and in vivo protective immunity.
Tomita S; Fujiwara H; Yamane Y; Sano S; Nakajima H; Izumi Y; Arai H; Kawanishi Y; Tsuchida T; Hamaoka T
Jpn J Cancer Res; 1986 Feb; 77(2):182-9. PubMed ID: 3082830
[TBL] [Abstract][Full Text] [Related]
2. The role of tumor-specific Lyt-1+2- T cells in eradicating tumor cells in vivo. I. Lyt-1+2- T cells do not necessarily require recruitment of host's cytotoxic T cell precursors for implementation of in vivo immunity.
Fujiwara H; Fukuzawa M; Yoshioka T; Nakajima H; Hamaoka T
J Immunol; 1984 Sep; 133(3):1671-6. PubMed ID: 6205091
[TBL] [Abstract][Full Text] [Related]
3. Augmentation of antitumor immune response by trinitrophenyl (TNP)-reactive helper T-cells: enhanced induction of tumor-specific Lyt-1+2- T-cell-mediated delayed-type hypersensitivity from spleen cells of tumor-bearing mice by TNP helpers.
Suda T; Fujiwara H; Mizushima Y; Shearer GM; Hamaoka T
J Natl Cancer Inst; 1986 Dec; 77(6):1267-72. PubMed ID: 2948049
[TBL] [Abstract][Full Text] [Related]
4. Enhanced induction of tumor-specific Lyt-1+2- T cell-mediated protective immunity by in vivo administration of interleukin 1.
Izumi Y; Tsuchida T; Okuno K; Fujiwara H; Hamaoka T
Jpn J Cancer Res; 1985 Sep; 76(9):863-70. PubMed ID: 3932286
[TBL] [Abstract][Full Text] [Related]
5. T-T cell interaction in the induction of delayed-type hypersensitivity (DTH) responses: vaccinia virus-reactive helper T cell activity involved in enhanced in vivo induction of DTH responses and its application to augmentation of tumor-specific DTH responses.
Takai Y; Kosugi A; Yoshioka T; Tomita S; Fujiwara H; Hamaoka T
J Immunol; 1985 Jan; 134(1):108-13. PubMed ID: 3155458
[TBL] [Abstract][Full Text] [Related]
6. The mechanism of tumor growth inhibition by tumor-specific Lyt-1+2-T cells. I. Antitumor effect of Lyt-1+2-T cells depends on the existence of adherent cells.
Fujiwara H; Takai Y; Sakamoto K; Hamaoka T
J Immunol; 1985 Sep; 135(3):2187-91. PubMed ID: 3874911
[TBL] [Abstract][Full Text] [Related]
7. Studies on macrophage-activating factor (MAF) in antitumor immune responses. I. Tumor-specific Lyt-1+2- T cells are required for producing MAF able to generate cytolytic as well as cytostatic macrophages.
Nakajima H; Fujiwara H; Takai Y; Izumi Y; Sano S; Tsuchida T; Hamaoka T
J Immunol; 1985 Sep; 135(3):2199-205. PubMed ID: 3894520
[TBL] [Abstract][Full Text] [Related]
8. The role of anti-asialo GM1 antibody-sensitive cells in the implementation of tumor-specific T cell-mediated immunity in vivo.
Yoshioka T; Sato S; Fujiwara H; Hamaoka T
Jpn J Cancer Res; 1986 Aug; 77(8):825-32. PubMed ID: 3093429
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of in vivo generation of cytotoxic effector cells against tumor in tumor-bearing mice.
Fuyama S; Yamamoto H; Fujii Y; Arai S
Cancer Res; 1986 Nov; 46(11):5548-52. PubMed ID: 2428480
[TBL] [Abstract][Full Text] [Related]
10. Helper T cells against tumor-associated antigens (TAA): preferential induction of helper T cell activities involved in anti-TAA cytotoxic T lymphocyte and antibody responses.
Fujiwara H; Yoshioka T; Shima J; Kosugi A; Itoh K; Hamaoka T
J Immunol; 1986 Apr; 136(7):2715-9. PubMed ID: 3005417
[TBL] [Abstract][Full Text] [Related]
11. Differential ability of tumor-unique and cross-reactive antigen(s) on two murine hepatoma cell lines to induce Lyt-1+2- T cells responsible for in vivo protective immunity.
Shima J; Yoshioka T; Kosugi A; Ogata M; Fujiwara H; Hamaoka T; Ueda S; Kato S
Biken J; 1987 Mar; 30(1):1-8. PubMed ID: 2445335
[TBL] [Abstract][Full Text] [Related]
12. Requirements of adherent cells for activating Lyt-1+2- T cells as well as for functioning as antitumor effectors activated by factor(s) from Lyt-1+2- T cells.
Sakamoto K; Fujiwara H; Nakajima H; Yoshioka T; Takai Y; Hamaoka T
Jpn J Cancer Res; 1986 Nov; 77(11):1142-52. PubMed ID: 3098724
[TBL] [Abstract][Full Text] [Related]
13. Cellular basis of immunologic interactions in adoptive T cell therapy of established metastases from a syngeneic murine sarcoma.
Ward BA; Shu S; Chou T; Perry-Lalley D; Chang AE
J Immunol; 1988 Aug; 141(3):1047-53. PubMed ID: 3260908
[TBL] [Abstract][Full Text] [Related]
14. Distinct subsets of accessory cells activate Thy-1+ triple negative (CD3-, CD4-, CD8-) cells and Th-1 delayed-type hypersensitivity effector T cells.
Matsushima GK; Stohlman SA
J Immunol; 1991 May; 146(10):3322-31. PubMed ID: 1673982
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of passive antilisterial immunity and change of Lyt phenotype following in vitro stimulation of murine lymphoid cells from immune donors.
Barry RA; Hinrichs DJ
Clin Invest Med; 1984; 7(4):303-9. PubMed ID: 6442653
[TBL] [Abstract][Full Text] [Related]
16. Cell-mediated immune responses to syngeneic tumors. I. Identification of two distinct CTL effector pathways which differ in antigen specificity, genetic regulation, and cell surface phenotype.
Lynch DH; Daynes RA; Hodes RJ
J Immunol; 1986 Feb; 136(4):1521-7. PubMed ID: 2418117
[TBL] [Abstract][Full Text] [Related]
17. Enhanced TNP-reactive helper T cell activity and its utilization in the induction of amplified tumor immunity that results in tumor regression.
Fujiwara H; Moriyama Y; Suda T; Tsuchida T; Shearer GM; Hamaoka T
J Immunol; 1984 Mar; 132(3):1571-7. PubMed ID: 6198397
[TBL] [Abstract][Full Text] [Related]
18. The augmentation of tumor-specific immunity by virus help. III. Enhanced generation of tumor-specific Lyt-1+2- T cells is responsible for augmented tumor immunity in vivo.
Yoshioka T; Fukuzawa M; Takai Y; Wakamiya N; Ueda S; Kato S; Fujiwara H; Hamaoka T
Cancer Immunol Immunother; 1986; 21(3):193-8. PubMed ID: 2938736
[TBL] [Abstract][Full Text] [Related]
19. Establishment of tumor-specific immunotherapy model utilizing vaccinia virus-reactive helper T cell activity.
Shimizu Y; Hasumi K; Masubuchi K; Okudaira Y
Eur J Immunol; 1988 Nov; 18(11):1773-8. PubMed ID: 2974424
[TBL] [Abstract][Full Text] [Related]
20. Enrichment of antitumor effector cells that are effective in vivo from spleen cells of tumor-bearing mice through the use of Dolichos biflorus lectin.
Okada T; Ezawa K; Imai Y; Osawa T
Cancer Res; 1986 Nov; 46(11):5611-7. PubMed ID: 3093067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
